After Reaching Milestone, Is Capricor Therapeutics Incorporated (NASDAQ:CAPR)’s Short Interest Revealing Something?

September 17, 2017 - By Migdalia James

 After Reaching Milestone, Is Capricor Therapeutics Incorporated (NASDAQ:CAPR)’s Short Interest Revealing Something?

Investors sentiment decreased to 1 in 2016 Q4. Its down 0.33, from 1.33 in 2016Q3. It turned negative, as 4 investors sold Capricor Therapeutics Inc shares while 2 reduced holdings. 2 funds opened positions while 4 raised stakes. 764,994 shares or 9.01% less from 840,701 shares in 2016Q3 were reported.
Vanguard Gp Incorporated stated it has 50,790 shares. Morgan Stanley reported 0% in Capricor Therapeutics Inc (NASDAQ:CAPR). Perceptive Lc accumulated 4,000 shares. Blackrock Fund Advsrs owns 16,598 shares. Brown Advisory holds 71,065 shares. Moreover, Goldman Sachs Grp Inc Inc has 0% invested in Capricor Therapeutics Inc (NASDAQ:CAPR). Geode Cap accumulated 43,929 shares. Architects accumulated 2,000 shares. Blackrock Advisors Ltd Liability Com holds 1,665 shares or 0% of its portfolio. Granite Point Cap Mgmt Lp, a Massachusetts-based fund reported 67,500 shares. Susquehanna Interest Gru Ltd Liability Partnership reported 14,319 shares or 0% of all its holdings. The New Jersey-based Blackrock Invest Ltd Liability has invested 0% in Capricor Therapeutics Inc (NASDAQ:CAPR). Bancorp Of America De stated it has 0% in Capricor Therapeutics Inc (NASDAQ:CAPR). Sabby Management Limited Com has 0.06% invested in Capricor Therapeutics Inc (NASDAQ:CAPR). Cordasco Financial Networks reported 0.01% in Capricor Therapeutics Inc (NASDAQ:CAPR).

Since May 9, 2017, it had 3 insider buys, and 0 insider sales for $3.66 million activity. $3.55M worth of Capricor Therapeutics Inc (NASDAQ:CAPR) shares were bought by CEDARS SINAI MEDICAL CENTER. $31,000 worth of Capricor Therapeutics Inc (NASDAQ:CAPR) was bought by Manzo Louis. Musket David B bought $77,500 worth of Capricor Therapeutics Inc (NASDAQ:CAPR) on Tuesday, May 9.

The stock of Capricor Therapeutics Incorporated (NASDAQ:CAPR) registered an increase of 16.72% in short interest. CAPR’s total short interest was 916,400 shares in September as published by FINRA. Its up 16.72% from 785,100 shares, reported previously. With 175,700 shares average volume, it will take short sellers 5 days to cover their CAPR’s short positions. The short interest to Capricor Therapeutics Incorporated’s float is 8.88%.

The stock increased 3.09% or $0.03 on September 15, reaching $1. About 1.08M shares traded or 265.46% up from the average. Capricor Therapeutics Inc (NASDAQ:CAPR) has declined 72.31% since September 17, 2016 and is downtrending. It has underperformed by 89.01% the S&P500.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology firm focused on the discovery, development and commercialization of therapeutics. The company has market cap of $23.50 million. The Firm focuses on discovering, developing and commercializing regenerative medicine and large molecule products for the treatment of disease, with a primary focus on the treatment of cardiovascular diseases, including orphan indications. It currently has negative earnings. The Company’s product candidate, CAP-1002, a cardiosphere-derived cell product, is being tested in the ALLSTAR Phase II clinical study on patients having suffered a myocardial infarction , while the DYNAMIC clinical study is testing CAP-1002 in patients in the advanced-stage of heart failure.

Capricor Therapeutics Inc (NASDAQ:CAPR) Ratings Coverage

Among 2 analysts covering Capricor Therapeutics (NASDAQ:CAPR), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Capricor Therapeutics had 4 analyst reports since June 15, 2016 according to SRatingsIntel. The rating was reinitiated by H.C. Wainwright with “Buy” on Wednesday, July 6. The firm earned “Buy” rating on Friday, September 15 by H.C. Wainwright. The rating was maintained by H.C. Wainwright with “Buy” on Monday, July 10. The firm earned “Buy” rating on Wednesday, June 15 by Roth Capital.

More notable recent Capricor Therapeutics Inc (NASDAQ:CAPR) news were published by: Prnewswire.com which released: “Capricor Receives Rare Pediatric Disease Designation from FDA for CAP-1002 for …” on July 18, 2017, also Seekingalpha.com with their article: “Capricor Trial Failure In Heart Disease Might Offer Another Opportunity” published on May 15, 2017, Prnewswire.com published: “Capricor Therapeutics Announces Plans to Expand Clinical Development Program …” on November 10, 2016. More interesting news about Capricor Therapeutics Inc (NASDAQ:CAPR) were released by: Prnewswire.com and their article: “Capricor Therapeutics Completes Enrollment in Phase II ALLSTAR Clinical Trial” published on October 05, 2016 as well as Prnewswire.com‘s news article titled: “Capricor Therapeutics Reports First Quarter 2017 Financial Results and …” with publication date: May 15, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.